Jordi Martí, has been appointed CEO of Celgene Spain
The biopharmaceutical company, which trades on Nasdaq, has recently acquired Abraxis Bioscience reinforcing in the area of oncology.
By Biocat
Jordi Martí, who recently announced that he has closed a period of 21 years in charge of the company Amgen Spain-Portugal, has joined Celgene Spain as CEO. Martí replaces Tom Cavanaugh, who had been leading the subsidiary since the beginning of 2011.
Founded in the mid-eighties in New Jersey (USA), Celgene is a major global biopharmaceutical company, listed on Nasdaq and is specialized in the research, development and commercialization of innovative medicines for the treatment of cancer and diseases of the immune system. Among their therapies already in the market, there is Revlimid® (lenalidomide), an immunomodulatory drug for the treatment of multiple myeloma and Vidaza® (azacitidine), an epigenetic therapy used for myelodysplastic syndromes.
In Spain, Celgene activity began in 2006 and established its headquarters in Madrid. In the last five years has invested 30% of its revenues in R & D, and has collaborated with organizations such as the Spanish Myeloma Group and the Haematology Treatment Spanish Program.
Last October, it acquired the US company Abraxis Bioscience for USD 2,900M, an operation which positioned the company as a world leader in cancer treatment.
We recommend you the interview Jordi Martí granted to Biocat last October 2011.